April 15, 2026
Lilly to acquire CrossBridge Bio for up to $300m
Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash, comprising an upfront payment and a milestone payment tied to specified development progress.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







